FSD Pharma: Developing Novel Solutions for Brain & Inflammatory Disorders
FSD Pharma (CSE: HUGE, NASDAQ: HUGE) is bringing innovative neuro and inflammatory disorders therapies to millions of patients in need.
FSD Pharma is bringing innovative neuro and inflammatory disorders therapies to millions of patients in need.
FSD Pharma, with only 38.4 million shares issued/outstanding, is a biotechnology company with three drug candidates in different stages of development.
FSD BioSciences, Inc. (“FSD BioSciences”), a wholly-owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Lucid Psycheceuticals Inc. (“Lucid”), a wholly-owned subsidiary, is focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.
For more information on FSD Pharma Inc. (CSE: HUGE, NASDAQ: HUGE) please click the request investor info button.
Latest Articles
Hot Companies
You might also like
BTV Showcases Contango Ore, Critical Elements Lithium, Dryden Gold, FireFox Gold, Kirkland Lake, Klondike Gold, and Selkirk Mines
This week, BTV - Business Television we feature growth-focused mining companies advancing major projects across North America and Europe. From emerging producers and strategic combinations to high-grade exploration and critical mineral development, this episode highlights the next wave of opportunity in the resource sector, including:
Selkirk Copper: A Yukon restart positioned to deliver new Canadian copper supply by 2028
A 50,000-metre drill program began last summer to expand understanding of the resource and guide updated mine design. The goal is to define a 12–15 year mine life while refreshing permits and engineering.
